Albasheer Osama, Abdelwahab Siddig Ibrahim, Alqassim Ahmad, Alessa Hatim, Madkhali Afnan, Hakami Afaf, Mohieddin Jamal, Ahmed Anas E, Ali Suhaila, Abdelmola Amani, Oraibi Omar, Mohamed Amal H, Gohal Gassem, Altraifi Ahmed Abdallah, Medani Isameldin E
Department of Family and Community Medicine, College of Medicine, Jazan University, Jazan, 45142, Saudi Arabia.
Health Research Centre, Jazan University, Jazan, Saudi Arabia.
J Health Popul Nutr. 2025 May 29;44(1):176. doi: 10.1186/s41043-025-00881-8.
Hypovitaminosis D or vitamin D deficiency is a significant public health issue. Several vitamin D preparations are currently available. However, there is no consensus on the optimal dose and duration of vitamin D supplementation. This study aimed to evaluate the effects of vitamin D supplementation on symptoms and clinical outcomes in adults with insufficient or deficient baseline vitamin D levels.
A pre-post two-month intervention with 50,000 IU vitamin D3 supplementation for adults with documented insufficient or deficient baseline vitamin D levels, presented at Jazan University Hospital from August to December 2022.
Of the 204 participants, 65.1% had baseline vitamin D levels < 30 nmol/L. Vitamin D insufficiency is more prevalent among females, older adults, married individuals, and those with low income. However, these differences were not statistically significant (p > 0.5). The symptoms and clinical outcomes were significantly improved after 2 months of vitamin D3 supplementation for the participants who achieved vitamin D levels > 50 nmol/L (p = 0.000). After adjusting for multiple confounders, the significant determinants of symptom improvement and clinical outcomes post-supplementation included education level, income, smoking status, and baseline vitamin D level.
Hypovitaminosis D or vitamin D deficiency was observed in study participants. The use of a 50,000 IU cholecalciferol (vitamin D3) orally once per week for two months is sufficient to improve the symptoms and clinical outcomes of vitamin D deficiency. However, long-term follow-up could better assess the sustainability of benefits and explore long-term outcomes, such as the risk of deficiency recurrence.
Not applicable.
维生素D缺乏症是一个重大的公共卫生问题。目前有几种维生素D制剂可供使用。然而，对于维生素D补充的最佳剂量和持续时间尚无共识。本研究旨在评估维生素D补充对基线维生素D水平不足或缺乏的成年人的症状和临床结局的影响。
对2022年8月至12月在吉赞大学医院就诊的基线维生素D水平记录为不足或缺乏的成年人进行为期两个月的前后干预，补充50,000 IU维生素D3。
在204名参与者中，65.1%的人基线维生素D水平<30 nmol/L。维生素D不足在女性、老年人、已婚者和低收入者中更为普遍。然而，这些差异无统计学意义（p>0.5）。对于维生素D水平>50 nmol/L的参与者，补充维生素D3 2个月后症状和临床结局有显著改善（p = 0.000）。在调整多个混杂因素后，补充后症状改善和临床结局的显著决定因素包括教育水平、收入、吸烟状况和基线维生素D水平。
在研究参与者中观察到维生素D缺乏症。每周口服一次50,000 IU胆钙化醇（维生素D3），持续两个月，足以改善维生素D缺乏的症状和临床结局。然而，长期随访可以更好地评估益处的可持续性，并探索长期结局，如缺乏复发的风险。
不适用。
